Fennec Pharmaceuticals (FENC) vs REGENXBIO (RGNX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Fennec Pharmaceuticals (FENC) has outperformed REGENXBIO (RGNX) over the past year, gaining 66.1% versus a loss of 39.3%. Over five years, FENC leads with a +35.8% price change compared with -76.9% for RGNX. REGENXBIO is the larger company by market cap ($473.4 million vs $462.1 million), about 1.0 times the size.
Fennec Pharmaceuticals converts more of its revenue into profit, with a net margin of -21.8% versus -113.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FENC | RGNX |
|---|---|---|
| Share price | $13.09 | $7.16 |
| Market cap | $462.14M | $473.44M |
| 1-day change | -2.68% | -0.28% |
| YTD return | +70.00% | -50.28% |
| 1-year return | +66.12% | -39.32% |
| 5-year return | +35.79% | -76.87% |
| P/E ratio (TTM) | 436.33 | — |
| Forward P/E | 12.47 | — |
| EPS (TTM) | $0.03 | $-3.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $44.64M | $170.44M |
| Revenue growth (YoY) | -6.09% | +104.54% |
| Net income (latest FY) | $-9.74M | $-193.88M |
| Operating margin | -14.07% | -94.58% |
| Net margin | -21.82% | -113.75% |
| 52-week high | $13.85 | $16.19 |
| 52-week low | $5.65 | $5.46 |
| Distance from 52-week high | -5.49% | -55.78% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +34.45% | +198.88% |
| Average volume | 220.87K | 1.39M |
| Shares outstanding | 35.31M | 66.12M |
| Employees | 35 | 371 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FENC has outperformed RGNX by 105.4 percentage points over the past year.
- Fennec Pharmaceuticals is more profitable, keeping -21.8 cents of every revenue dollar as net income versus -113.8 cents for REGENXBIO.
- REGENXBIO grew revenue faster in its latest fiscal year (+104.54% vs -6.09%).
About Fennec Pharmaceuticals
FENC stock →Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 35 employees
About REGENXBIO
RGNX stock →REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 371 employees
FENC vs RGNX FAQ
Which is bigger, Fennec Pharmaceuticals or REGENXBIO?
REGENXBIO (RGNX) is larger, with a market capitalization of $473.44M compared with $462.14M for Fennec Pharmaceuticals (FENC).
Which stock has performed better over the past year, FENC or RGNX?
FENC returned +66.12% over the past 12 months, compared with -39.32% for RGNX (price return, excluding dividends). Past performance does not predict future results.
Are Fennec Pharmaceuticals and REGENXBIO in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.